|
|
|
| Visual analysis on research hotspot and trend of primary liver cancer in the field of traditional Chinese medicine based on CiteSpace#br# |
| YU Huibo1，2 HU Jiaqi1，2 CHEN Shuntai1，2 CHEN Xin1 ZHENG Honggang1 |
1.Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China;
2.Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China |
|
|
|
Abstract Objective To analyze the research hotspot and trend of primary liver cancer in the field of Chinese medicine in recent 20 years by using visualization. Methods With “traditional Chinese medicine” and “primary liver cancer” as the research topics, Chinese literatures were searched from CNKI database from January 2000 to October 2020. The authors, institutions and keywords of these literatures were visually analyzed by CiteSpace. Results A total of 2488 Chinese literatures were included, the annual published articles showed a gradually increasing trend. Ling Changquan was the most prolific author, forming teams with Ling Changquan, Fang Zhaoqin and Chen Chuang as the core. Shanghai University of Traditional Chinese Medicine was the most prolific institutions, and the cooperation between different institutions was quite different. Removing subject words relevant keywords, the top three keywords were “review”, “Compound Kushen Injection” and “intervention therapy”, the top three centrality keywords were “apoptosis”, “mouse” and “Compound Kushen Injection”. A total of 13 clusters and 24 emergent words were appeared. Conclusion In recent 20 years, the research content of primary liver cancer in the field of traditional Chinese medicine in China is rich. At present, the hotspots are summarizing clinical experience and the molecular biological mechanism of traditional Chinese medicine improving liver function, immune function and cancer pain in patients with liver cancer.
|
|
|
|
|
|
[1] 赫捷.临床肿瘤学[M].北京：人民卫生出版社，2016：448-449.
[2] Sung H，Ferlay J，Siegel RL，et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2021，71（3）：209-249.
[3] 孙燕，石远凯.内科治疗手册[M].北京：人民卫生出版社，2012：543.
[4] 吴玉潇，盛庆寿.中医药治疗原发性肝癌的研究进展[J].广西医学，2020，42（4）：483-485.
[5] Allemani C，Matsuda T，Di Carlo V，et al. Global surveillance of trends in cancer survival 2000-14 （CONCORD-3）：analysis of individual records of 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries [J]. Lancet，2018，391（10125）：1023-1075.
[6] 陈亚栋，莫春梅，荣震，等.中药联合肝动脉栓塞化疗术（TACE）治疗原发性肝癌研究进展[J].辽宁中医药大学学报，2019，21（1）：87-90.
[7] 陈悦，陈超美，刘则渊，等.CiteSpace知识图谱的方法论功能[J].科学学研究，2015，33（2）：242-253.
[8] Synnestvedt MB，Chen C，Holmes JH. CiteSpace Ⅱ：visualization and knowledge discovery in bibliographic databases [J]. AMIA Annu Symp Proc，2005，2005：724-728.
[9] 我国16个重点病种的国家中医临床研究基地论文统计表（2008年～2013年）[J].世界科学技术-中医药现代化，2013，15（5）：1161-1261.
[10] 范宏伟，周琪，黄卫东.医学院校附属医院临床医生科研能力影响因素分析[J].中国医院管理，2015，35（8）：53-55.
[11] 彭轶霞.消肝积汤治疗原发性肝癌50例[J].陕西中医学院学报，2001，24（4）：38.
[12] 王文志，宓余强.原发性肝癌的中医病因病机浅析[J].中医学报，2013，28（1）：14-15.
[13] 杨硕，郑洪新.郑洪新教授治疗肝癌四法[J].辽宁中医药大学学报，2020，22（3）：189-192.
[14] 郭丹丹，黄秋思，张金良，等.张金良治疗肝癌的临床经验总结[J].中医药导报，2019，25（21）：102-104.
[15] 成扬，倪赛赛，陈建杰.陈建杰教授运用中医辨证论治治疗肝癌术后经验探析[J].海南医学院学报，2020，26（11）：861-863，867.
[16] 程卫东，赵健雄，徐瑞峰，等.扶正抑瘤颗粒对小鼠肝癌细胞H22凋亡的影响[J].中国中医药科技，2005，12（3）：146-147.
[17] 李素素.三物白散通过调节肠道菌群介导肝癌免疫应答的机制研究[D].南京：南京中医药大学，2020：36.
[18] 唐莹.参桃软肝方对HBx蛋白导致的肝癌DNA甲基化状态的影响[D].广州：广州中医药大学，2018：55.
[19] 卢伟.癌痛平胶囊治疗癌痛的临床研究及机制探讨[D].南京：南京中医药大学，2012：62-63.
[20] 王会仓，王秀明.复方漏芦汤治疗原发性肝癌30例临床观察[J].湖南中医杂志，2008，24（1）：26-27.
[21] 覃艳春，莫春梅，蒋锐沅，等.中药联合索拉菲尼治疗原发性肝癌的Meta分析[J].世界中西医结合杂志，2020， 15（9）：1597-1602.
[22] 胡振斌，冉思邈，吕建林，等.抗癌散结方治疗原发性肝癌介入术后临床观察[J].辽宁中医药大学学报，2019， 21（2）：9-12.
[23] 李雪纯，高司成，戴瑶瑶，等.中医与中西医结合治疗原发性肝癌的新进展[J].现代中西医结合杂志，2021，30（6）：681-684.
[24] 王悦华，王珍.医本家整体治疗策略在肿瘤治疗设计中的作用[J].医学研究杂志，2011，40（7）：140-144. |
|
|
|
